Alkem Laboratories Q4 FY26 earnings: dates, estimates

Why Alkem’s next results matter

Alkem Laboratories (NSE: ALKEM) is in focus ahead of its next quarterly earnings announcement, a key event for pharma investors during the April to May 2026 results season. Multiple market trackers and previews point to May 2026 as the reporting window for Alkem’s Q4 FY26 (January to March 2026) numbers, with different sources citing different specific dates.

The stock is widely tracked because the company’s quarterly performance has shown a mix of growth on a year-on-year basis and pressure on some sequential metrics. For investors, the upcoming earnings will help validate whether recent revenue growth is translating into stable profitability and whether management commentary addresses key operating variables such as international sales momentum and margins.

Earnings dates: what’s confirmed in available disclosures

The information available in the provided text points to two May 2026 dates:

• One dataset lists the upcoming earnings date as May 28, 2026, and separately notes that Alkem is “set to release its Q4 2026 earnings on May 28, 2026.” It also mentions a Q4FY26 results conference call on May 28.
• Another preview states Alkem is scheduled to announce Q4 FY26 financial results on May 8, 2026, describing a board meeting to consider and approve audited financial statements for Q4 FY26 and the full year FY26.

The company’s last reported earnings date in the text is Q3 FY25-26 on February 13, 2026.

Q3 FY26 snapshot: revenue, profit and margins signals

The text provides Q3 FY26 operational metrics in more than one format. A quarterly summary lists:

• Revenue: ₹3,736 crore (QoQ -6.60%, YoY +10.74%)
• Gross profit: ₹732 crore (QoQ -11.38%, YoY +8.73%)
• Net profit: ₹653 crore (QoQ -16.17%, YoY +1.99%)

Another description of Q3 FY26 performance states total revenue grew 10.7% to ₹37,368 million, which translates to ₹3,736.8 crore, and also cites EBITDA of ₹8,280 million (₹828 crore). The same passage mentions net profit of ₹6,360 million (₹636 crore) and an interim dividend of ₹43 per share, along with a strategic acquisition announcement involving Swiss medical devices company Occlutech.

Taken together, the Q3 data points to clear year-on-year revenue growth, while sequential (quarter-on-quarter) changes in gross profit and net profit are shown as negative in one summary.

What analysts expect for Q4 FY26: revenue and PAT ranges

A dedicated estimates table in the provided text sets out the following expectations for Q4 FY26:

• Revenue estimate: ₹3,200 to ₹3,400 crore
• PAT estimate: ₹420 to ₹470 crore
• A key ratio/margin range: 17% to 19%

That same table compares these ranges against Q3 FY26 actual revenue of ₹3,147 crore and Q3 FY26 PAT of ₹413 crore, highlighting that the estimate implies sequential improvement.

Separately, another data provider’s consensus figures are presented in “billion” units for Q4 2026 revenue as 35.30 billion, with the previous quarter’s actual revenue shown as 37.37 billion. Expressed in the Indian crore format (billion-to-crore unit conversion), these correspond to roughly ₹3,530 crore and ₹3,737 crore, aligning closely with the ₹3,736 crore revenue cited for Q3 in the same set of notes.

How the previous quarter compared with expectations

For the quarter ended December 31, 2025, the text states:

• Actual revenue was 37.37 billion versus an expectation of 37.60 billion (miss of -0.61%)
• Actual earnings were 53.19 per share versus an expectation of 57.50 per share (miss of -7.50%)

These figures matter because near-term stock reactions often hinge on the gap between reported numbers and consensus expectations, especially around margins and profit.

Dividend signals investors are watching

The text explicitly mentions two dividend references:

• An interim dividend of ₹43 per share, declared alongside Q3 FY26 performance commentary.
• A separate note that Alkem “has declared a dividend of ₹43.00 on 20 Feb, 2026.”

In addition, another results-related highlight set mentions a final dividend of ₹8 per share in connection with a consolidated YoY summary where revenue is shown at ₹3,144 crore and net profit at ₹306 crore. Since these dividend figures are presented across different result summaries in the source text, investors typically verify the relevant period and filing when tracking payout decisions.

Market context: price targets and where the stock was cited

The text includes multiple reference points on valuation and price levels:

• One preview states the stock was “trading at ₹4,200” and cites an analyst 12-month target range of ₹4,400 to ₹5,500, described as a Hold/Buy consensus.
• The same write-up also mentions a short-term range of ₹4,200 to ₹4,800.
• Another line notes that as of 10-03-2026, Alkem Laboratories was trading at ₹5,567.50 per share.

These snapshots show that the stock level depends on the date and the dataset referenced, so investors typically compare them to exchange quotes and the date of the underlying note.

Key items to track in the results and call

Across the provided previews, the commonly highlighted monitor points include:

• Revenue performance versus estimates (including the ₹3,200 to ₹3,400 crore range)
• PAT performance versus estimates (₹420 to ₹470 crore)
• Management guidance for FY27
• Commentary on macro headwinds (examples listed include tariffs, crude prices, and rural demand)
• Updates on US revenue performance and product pipeline
• Dividend declaration expectations for final or special payouts

Summary table: dates, Q3 base and Q4 expectations

What this means for investors

The main takeaway from the provided information is that Alkem is heading into a closely watched Q4 FY26 update with multiple published expectations around revenue and profits. The near-term focus remains on how reported numbers compare against estimate ranges, and whether margins trend closer to the 17% to 19% band mentioned in the Q4 preview.

Investors also tend to watch the accompanying conference call for clarity on international performance, any update related to earlier announced strategic moves, and the company’s positioning for FY27.

Conclusion

Alkem Laboratories’ next earnings announcement is expected in May 2026, with the provided sources citing May 8 and May 28 as key dates. With Q3 FY26 revenue around ₹3,736 crore and Q4 estimates clustered around ₹3,200 to ₹3,400 crore revenue and ₹420 to ₹470 crore PAT, the upcoming release and any scheduled call will be a key checkpoint for investors tracking margins, profitability, and guidance.